Bio-Reference Laboratories, Inc. Responds to an Employee Wrongful Termination Suit Filed Against it as Baseless and Without

Bio-Reference Laboratories, Inc. Responds to an Employee Wrongful Termination
Suit Filed Against it as Baseless and Without Merit

ELMWOOD PARK, N.J., April 12, 2013 (GLOBE NEWSWIRE) -- Bio-Reference
Laboratories, Inc. (Nasdaq:BRLI) strongly denounced and denied the allegations
of a complaint that has been filed against the Company in the Superior Court
of New Jersey by an apparently disgruntled, former employee. The Company has
indicated that it will vigorously defend this case, if it proceeds, and will
seek to vindicate itself through all means against the frivolous allegations.

The Company noted that earlier this week a web-based blog had posted the
complaint against the Company, which has not yet been served on the Company
and was unknown to the Company prior to the blog report.However, based on
what was posted on the blog, the Company has completed a preliminary review of
the allegations and has determined that the complaint is baseless, frivolous
and totally without merit.The complaint describes a series of events that are
unsupported by facts and seeks compensation for non-existent damages.The
Company has policies and procedures in place that are designed to prevent the
possibility of compliance violations along the lines of those alleged and that
it has quality assurance programs in place that verify full compliance during
the period of time alleged in the complaint.The Company's preliminary review
of all electronic requisitions (the method that was used in this office)
submitted by the account during the time when the plaintiff was assigned at
that office to be a phlebotomist reveals no apparent Medicare or other billing
issues.The Company believes it has found no evidence that any Medicare
patients, drawn by the physician's staff, were billed by the Company to
Medicare for venipuncture fees. The Company also believes, based on its
preliminary review that the totality of blood draws involving the plaintiff
are miniscule in number and the amount of anticipated reimbursement from those
phlebotomy services billed to Medicare from the account over the period the
plaintiff worked at the location was less than $250. In addition, the Company
believes that the billing practices relating to this account are consistent
and compliant with Medicare and Medicaid regulations.

It should be noted that the former employee was terminated by the Company in
the ordinary course of business in April 2011 and that she filed no internal
or external complaints with or against the Company until the lawsuit was
reported in the previously mentioned blog report.The Company believes that
the circumstances relating to the filing of the complaint and the allegations
contained in it defy logic and credibility.In this regard, while the case has
been described in the internet blogs as a "whistleblower" suit, the Company is
unaware of any facts indicating that the Plaintiff ever engaged in any
whistleblowing activities, and this case is nothing more than a wrongful
termination suit filed by a disgruntled former employee nearly two years after
her discharge.

The Company will continue to investigate the allegations and the circumstances
of this case and will take all necessary and appropriate steps available under
the law.

About BioReference Laboratories, Inc.

BRLI is a clinical testing laboratory offering testing, information and
related services to physician offices, clinics, hospitals, employers and
governmental units.We believe that we are the fourth largest full-service
laboratory in the United States and the largest independent regional
laboratory in the Northeastern market.BRLI offers a comprehensive list of
laboratory testing services utilized by healthcare providers in the detection,
diagnosis, evaluation, monitoring and treatment of diseases.BRLI primarily
focuses on esoteric testing, molecular diagnostics, anatomical pathology,
women's health and correctional health care.

Statements included in this release that are not historical in nature, are
intended to be, and are hereby identified as "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995,
many of which are beyond our ability to control or predict. Forward-looking
statements may be identified by words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates," "will" or words of
similar meaning and include, but are not limited to, statements about the
expected future business and financial performance of Bio-Reference
Laboratories, Inc. and its subsidiaries. Statements looking forward in time
are included in this release pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Such statements involve
known and unknown risks and uncertainties that may cause the Company's actual
results in future periods to be materially different from any future
performance suggested herein. Risks and uncertainties that may affect the
future results of the company include, but are not limited to, adverse results
from future government investigations, lawsuits or private actions, including
the lawsuit described herein, the competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other and other risks and uncertainties
detailed from time to time in our filings with the Securities and Exchange
Commission.We undertake no obligation to publicly update or review any
forward-looking information, whether as a result of new information, future
developments or otherwise.


         Tara Mackay, Investor Relations
         (201) 791-2600
         (201) 791-1941 (fax)
Press spacebar to pause and continue. Press esc to stop.